Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically documented refractory or recurrent ovarian epithelial or fallopian tube cancer
• No borderline ovarian cancer
• Extra-ovarian papillary serous tumors eligible
• Must not be eligible for any higher priority phase II or III GOG protocol
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• GOG 0-2
• Life expectancy:
• Not specified
• Hematopoietic:
• Granulocyte count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic:
• SGOT no greater than 3 times upper limit of normal (ULN)
• Bilirubin no greater than 1.5 mg/dL
• Elevated levels of alkaline phosphatase allowed
• Renal:
• Creatinine no greater than 1.5 mg/dL
• Cardiovascular:
• No angina pectoris or clinically significant multifocal uncontrolled cardiac dysrhythmias
• No uncontrolled hypertension
• Other:
• No other active malignancy
• No prior malignancy within the past 5 years except nonmelanomatous skin cancer
• No active infection
• No underlying medical problem that would prevent compliance
• No known hypersensitivity to E. coli-derived drug preparations
• Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Not specified
• Chemotherapy:
• Must have received at least 1 prior platinum- and paclitaxel-based regimen
• At least 4 weeks since prior chemotherapy
• No prior topotecan and/or gemcitabine
• No prior chemotherapy for a different prior malignancy
• Endocrine therapy:
• Not specified
• Radiotherapy:
• No prior radiotherapy to more than 10% of bone marrow
• At least 2 weeks since limited field radiation therapy
• Surgery:
• Not specified